// App-Quantinova.ai

: Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Howard I. Scher

Principal Investigators

  • Ryon P Graf

  • Nicole A. Schreiber

  • Eric Winquist

  • Brigit McLaughlin

  • David Lu

  • Sarah Orr

  • Martin Fleisher

  • Lori Lowes

  • Amanda K. L. Anderson

  • Yipeng Wang

  • Ryan Vance Dittamore

  • Alison L Allan

  • Gerhardt Attard

  • Glenn Heller

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Epic Sciences, Inc., San Diego, CA

  • London Health Sciences Center, London, ON, Canada

  • London Regional Cancer Program, London Health Sciences Centre, London, ON, Canada

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

Locations

  • United States

  • Canada

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

Drug/Treatment

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved